Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) prescribed to treat pain, swelling, and stiffness caused by several forms of arthritis and other inflammatory conditions. Sold under the brand name Clinoril, it works by blocking the enzymes that produce inflammation in your body. It’s taken as an oral tablet, typically twice a day with food, and has a notably long duration of action that keeps it working between doses.
FDA-Approved Uses
Sulindac is approved for both short-term and long-term relief of five conditions:
- Osteoarthritis: the wear-and-tear arthritis that affects joint cartilage, most common in knees, hips, and hands.
- Rheumatoid arthritis: an autoimmune condition where the immune system attacks joint linings, causing chronic pain and swelling.
- Ankylosing spondylitis: a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints, causing stiffness and fusion over time.
- Acute painful shoulder: specifically bursitis or tendinitis in the shoulder, where fluid-filled cushions or tendons become inflamed.
- Acute gouty arthritis: sudden, intense joint inflammation triggered by uric acid crystal buildup, often in the big toe.
For the three chronic arthritis conditions, the standard starting dose is 150 mg twice daily. For acute gout, bursitis, or tendinitis, the dose is higher at 200 mg twice daily. The maximum is 400 mg per day regardless of the condition being treated.
How Quickly It Works
About half of people with osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis notice meaningful improvement within the first week. The rest may need additional time. This relatively prompt onset is partly due to sulindac’s pharmacology: the drug itself is a prodrug, meaning your body converts it into an active form (the sulfide metabolite) that has a long half-life of roughly 16 hours. That sustained activity is why twice-daily dosing is enough to maintain steady anti-inflammatory effects throughout the day.
Potential Role in Polyp Prevention
Beyond its approved uses for pain and inflammation, sulindac has drawn significant research attention for its ability to reduce precancerous growths in the colon. In people with familial adenomatous polyposis (FAP), a hereditary condition that causes hundreds of polyps to form in the colon, sulindac has shown the ability to shrink and reduce the number of those polyps.
A clinical trial reported by the National Cancer Institute found that combining sulindac with another drug reduced the number of colorectal polyps by approximately 70% over six months compared to placebo. Sulindac appears to work through two pathways here: it blocks the COX-2 enzyme (the same mechanism that reduces inflammation in joints) and also inhibits a separate chemical process involved in cell growth called polyamine activity. This dual action is what makes it particularly interesting for polyp prevention.
A large trial called PACES has also tested sulindac in colorectal cancer survivors to see whether it can reduce the risk of new polyps and second cancers over several years. This use remains investigational, not an approved indication, but it’s one reason sulindac occupies a unique niche among NSAIDs.
The Kidney-Sparing Advantage
One characteristic that sets sulindac apart from most other NSAIDs is its reported gentler effect on the kidneys. NSAIDs as a class can impair kidney function, particularly in people who are already vulnerable, such as those with liver cirrhosis and fluid retention. In a study comparing sulindac to ibuprofen in patients with cirrhosis, ibuprofen reduced kidney clearance rates in the most affected patients while sulindac had no measurable effect on kidney function.
The explanation appears to be straightforward: sulindac is simply a less potent inhibitor of the enzyme systems that regulate blood flow in the kidneys. Ibuprofen more aggressively suppresses those protective compounds, which is why kidney function can drop. This renal-sparing quality doesn’t mean sulindac is completely safe for people with kidney problems, but it has historically made it a preferred NSAID in certain higher-risk patients.
Common Side Effects
Sulindac shares the typical side effect profile of other NSAIDs. Gastrointestinal issues are the most frequent complaints: stomach pain, nausea, indigestion, and diarrhea or constipation. Like all NSAIDs, it carries a risk of stomach ulcers and GI bleeding, particularly with long-term use or in older adults. Taking it with food, as directed, helps reduce stomach irritation.
NSAIDs as a class also carry boxed warnings for increased risk of heart attack, stroke, and serious GI events. These risks rise with longer use and higher doses. Sulindac can also affect liver function in rare cases, so periodic monitoring may be appropriate during extended treatment. People who have had an allergic reaction to aspirin or other NSAIDs, including asthma symptoms triggered by these drugs, should not take sulindac.
How It Compares to Other NSAIDs
Sulindac occupies a middle ground among prescription NSAIDs. It’s not available over the counter like ibuprofen or naproxen, and it’s prescribed less frequently than newer options. But it has a few distinctive features that keep it relevant. Its long-acting metabolite means consistent anti-inflammatory coverage on a simple twice-daily schedule. Its kidney-sparing properties make it an option for patients where other NSAIDs might be riskier. And its activity against colorectal polyps gives it a research profile that no other common NSAID matches in quite the same way.
That said, it treats the same core set of conditions as other prescription NSAIDs. The choice between sulindac and alternatives like diclofenac, meloxicam, or naproxen typically comes down to individual response, side effect tolerance, and specific risk factors like kidney or liver health.